Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Cooper

Showing results (281-290 of 319) with videos related to

Pageof 32
Sort By:
Biorxiv : the Preprint Server for Biology|July 9, 2024
RNAi-mediated silencing of SOD1 profoundly extends survival and functional outcomes in ALS miceAlexandra Weiss, James W Gilbert, Iris Valeria Rivera Flores, et al.
Nucleic Acids Research|June 23, 2025
Systematic analysis of siRNA and mRNA features impacting fully chemically modified siRNA efficacySarah M Davis, Samuel Hildebrand, Hannah J MacMillan, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|May 11, 2025
RNAi-mediated silencing of SOD1 profoundly extends survival and functional outcomes in ALS miceAlexandra Weiss, James W Gilbert, Iris Valeria Rivera Flores, et al.
The Science of the Total Environment|May 9, 2016
Spatial patterns and environmental constraints on ecosystem services at a catchment scaleBridget A Emmett, David Cooper, Simon Smart, et al.
Lancet (London, England)|August 8, 2006
CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trialJintanat Ananworanich, Angèle Gayet-Ageron, Michelle Le Braz, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 7, 2016
Maraviroc, as a Switch Option, in HIV-1-infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Week 48 Results of the Randomized, Multicenter MARCH StudySarah Lilian Pett, Janaki Amin, Andrejz Horban, et al.
The New England Journal of Medicine|October 14, 2020
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine CandidatesEdward E Walsh, Robert W Frenck, Ann R Falsey, et al.
Medrxiv : the Preprint Server for Health Sciences|August 26, 2020
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy StudyEdward E Walsh, Robert Frenck, Ann R Falsey, et al.
Science (New York, N.Y.)|October 28, 2010
Scenarios for global biodiversity in the 21st centuryHenrique M Pereira, Paul W Leadley, Vânia Proença, et al.
Nature|August 14, 2020
Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adultsMark J Mulligan, Kirsten E Lyke, Nicholas Kitchin, et al.
Pageof 32

Showing results (281-290 of 319) with videos related to

Sort By:
Pageof 32
Biorxiv : the Preprint Server for Biology|July 9, 2024
RNAi-mediated silencing of SOD1 profoundly extends survival and functional outcomes in ALS miceAlexandra Weiss, James W Gilbert, Iris Valeria Rivera Flores, et al.
Nucleic Acids Research|June 23, 2025
Systematic analysis of siRNA and mRNA features impacting fully chemically modified siRNA efficacySarah M Davis, Samuel Hildebrand, Hannah J MacMillan, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|May 11, 2025
RNAi-mediated silencing of SOD1 profoundly extends survival and functional outcomes in ALS miceAlexandra Weiss, James W Gilbert, Iris Valeria Rivera Flores, et al.
The Science of the Total Environment|May 9, 2016
Spatial patterns and environmental constraints on ecosystem services at a catchment scaleBridget A Emmett, David Cooper, Simon Smart, et al.
Lancet (London, England)|August 8, 2006
CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trialJintanat Ananworanich, Angèle Gayet-Ageron, Michelle Le Braz, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 7, 2016
Maraviroc, as a Switch Option, in HIV-1-infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Week 48 Results of the Randomized, Multicenter MARCH StudySarah Lilian Pett, Janaki Amin, Andrejz Horban, et al.
The New England Journal of Medicine|October 14, 2020
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine CandidatesEdward E Walsh, Robert W Frenck, Ann R Falsey, et al.
Medrxiv : the Preprint Server for Health Sciences|August 26, 2020
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy StudyEdward E Walsh, Robert Frenck, Ann R Falsey, et al.
Science (New York, N.Y.)|October 28, 2010
Scenarios for global biodiversity in the 21st centuryHenrique M Pereira, Paul W Leadley, Vânia Proença, et al.
Nature|August 14, 2020
Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adultsMark J Mulligan, Kirsten E Lyke, Nicholas Kitchin, et al.
Pageof 32